Liver Fibrosis – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 87
Inquire Before Buying

Liver Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Liver Fibrosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Fibrosis.
- A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Liver Fibrosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Liver Fibrosis 10
Liver Fibrosis Therapeutics under Development by Companies 12
Liver Fibrosis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Liver Fibrosis Therapeutics - Products under Development by Companies 19
Liver Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Liver Fibrosis Therapeutics Development 21
Bristol-Myers Squibb Company 21
Gilead Sciences, Inc. 22
FibroGen, Inc. 23
Silence Therapeutics plc. 24
Genfit 25
La Jolla Pharmaceutical Company 26
LG Life Sciences, Ltd 27
Digna Biotech, S.L. 28
7TM Pharma A/S 29
GenKyoTex S.A. 30
Angion Biomedica Corp. 31
Virobay Inc. 32
Liver Fibrosis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
FG-3019 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TM-38837 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GFT-505 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P-17 Systemic - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GM-CT-01 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VBY-376 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BB-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GKT-137831 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
candesartan cilexetil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
irbesartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GS-6624 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CIGB-500 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AB-0023 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AM-095 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Raltegravir + Ritonavir-Boosted Protease Inhibitor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cytopro - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GM-CT-02 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GR-MD-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GR-MD-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ANG-4011 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-351 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Liver Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ANG-3298 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LC-280126 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79
Liver Fibrosis - Product Development Milestones 80
Featured News & Press Releases 80
Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports 80
Aug 07, 2012: Galectin Therapeutics Plans Clinical Trials For Early 2013 To Treat Fatty Liver Disease With Advanced Fibrosis After Recent FDA Meeting 80
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 81
May 10, 2012: Genfit Announces Preclinical Data Of GFT505 Promotes Liver Fibrosis Regression 82
Dec 16, 2011: Galectin Therapeutics Presents Preclinical Data On Treatment Of Fatty Liver Disease And Fibrosis At EASL 82
Nov 02, 2011: Promedior Announces Presentation Of Preclinical Data At AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis 83
Jul 12, 2011: GENFIT Announces First Results Of GFT505-210-5 Clinical Trial In Diabetic Patients 83
Apr 11, 2011: Fragment Of RegeneRx's Tß4 Inhibits Activation Of Liver Cells Responsible Fibrosis And Scar Formation 84
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 84
Oct 14, 2010: FibroGen Initiates Phase II Clinical Study To Evaluate Efficacy Of FG-3019 In Reversing Liver Fibrosis 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bristol-Myers Squibb Company, H2 2012 21
Gilead Sciences, Inc., H2 2012 22
FibroGen, Inc., H2 2012 23
Silence Therapeutics plc., H2 2012 24
Genfit, H2 2012 25
La Jolla Pharmaceutical Company, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Digna Biotech, S.L., H2 2012 28
7TM Pharma A/S, H2 2012 29
GenKyoTex S.A., H2 2012 30
Angion Biomedica Corp., H2 2012 31
Virobay Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79

List of Figures
Number of Products under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

  • Increase in Surgical Procedures Propelling the Anesthesia Drugs Market
    With increase in surgical operations and invasive medical tests, the market for anesthesia drugs has been growing at a steady pace. Anesthesia drugs can be broadly categorized into two types – general anesthesia drugs and local anesthesia drugs. Anesthetic drugs help in inducing sleep and preventing discomfort and pain during surgical procedures. By 2018, the [...]
  • Water Treatment Chemicals Market to be driven by Increasing Demand from Developing Economies
    The global market for water treatment chemicals is growing at a steady pace with rapid urbanization and high demand from end-users. Water treatment chemicals are used for treating municipal water as well as agricultural wastewater. With higher demand for clean, drinking water with increasing population and increase in the number of industries, the global market [...]
  • Rise in Prevalence of Allergic Diseases Driving the Global Allergy Diagnostics Market
    With rise in the incidences of allergic diseases in the world, the global allergy diagnostics market has also witnessed steady growth. In recent years, there has been an increase in the number of people suffering from different allergies, particularly food allergies and drug allergies. The number of people suffering from asthma has also increased in [...]
  • Global Video Surveillance Market Driven by Increasing Demand for Security
    The global market for video surveillance has been witnessing steady growth with increase in demand for advanced surveillance systems by different law enforcement agencies. Increase in adoption of video surveillance by different sectors such as banking and finance, healthcare, transportation, and retail is one of the major drivers in the market. In 2013, the global [...]
  • Global Empty Capsules Market Driven by Growth in Pharmaceutical Industry
    With rapid growth in the pharmaceutical industry, the market for empty capsules has also grown at a steady pace. Some of the factors which are driving the growth of the empty capsules market are rise in aging population which is increasing the demand for capsule based drugs, technological advancement and increase in demand from the [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • OpportunityAnalyzer: Acromegaly and Gigantism – Opportunity Analysis and Forecast to 2018
    Published: 18-Dec-2014        Price: US $7995 Onwards        Pages: 161
    GlobalData estimates the 2013 sales for acromegaly and gigantism at approximately $588m across the 6MM covered in this report. The market will grow moderately at a CAGR of 3.74% during the five year forecast period, generating sales of approximately $707m at the end of 2018. Growing at a CAGR of 4.58% and generating around 68% of global sales in 2018, the US market will experience twice the rate of growth of the 5EU market. Two major trends are visible among the pipeline drugs and research and d......
  • Russia: Eyeglasses (Optics) Market. Analysis and Forecast to 2017
    Published: 18-Dec-2014        Price: US $3281 Onwards        Pages: 257
    The report provides current information about the Russian Optical Glasses Market as of January 2012 The objectives of this market research report are to describe the state of the Russian sunglasses and eyeglasses (optics) market and to provide current information on volumes of production, exports, imports, consumption and market conditions, changes that occurred in 2010 and 2011, As well as to build a forecast of the industry in the medium term for the period before 2017 The optics market ......
  • 2014 Market Research Report on Global Disposable Syringe Industry
    Published: 17-Dec-2014        Price: US $2600 Onwards        Pages: 178
    This is a professional and depth research report on Global Disposable Syringe industry For overview analysis, the report introduces Disposable Syringe basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc For international and China market analysis, the report analyzes Disposable Syringe markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research o......
  • 2014 Market Research Report on Global Vitamin K3 Industry
    Published: 17-Dec-2014        Price: US $2600 Onwards        Pages: 180
    This is a professional and depth research report on Global Vitamin K3 industry For overview analysis, the report introduces Vitamin K3 basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc For international and China market analysis, the report analyzes Vitamin K3 markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of dif......
  • Kazakhstan Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 95
    BMI View: Plans to boost government spending on healthcare will be positive for the pharmaceutical industry as well as other participants in the healthcare sector. Over the longer term, the introduction of compulsory health insurance will create a large pool of funding for further growth. However, a key risk to our outlook is oil prices and their effect on Kazakh government revenues. Headline Expenditure Projections ? Pharmaceuticals: KZT273.92bn (USD1.80bn) in 2013 to KZT335.18bn (USD1.84bn) in......
  • Global Male Infertility Market 2015-2019
    Published: 17-Dec-2014        Price: US $2500 Onwards        Pages: 71
    Infertility is a widespread problem. In male infertility, the male fails to impregnate his female partner after a year of unprotected sex. Male infertility is due to a couple of factors including: Low sperm production Abnormal sperm function or Blockages that prevent the delivery of sperm. Hormonal disturbances to physical problems, or psychological problems can cause male infertility. In most cases, there are no obvious sign or symptoms of an infertility problem. 20 percent of the to......
  • Philippines Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 129
    BMI View: Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing population and high burden of disease profile. Generic medicines will continue to account for an increasing share of pharmaceutical sales in the Philippines, galvanised by expanding government provision of healthcare as well as improvements in generic drug distribution. This provides strong growth opportunities for generic drug manufacturers in an emerging market where economic growth will b......
  • Global Cystic Fibrosis Market 2015-2019
    Published: 17-Dec-2014        Price: US $3000 Onwards        Pages: 125
    Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country. Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and s......
  • United Kingdom Pharmaceuticals and Healthcare Report Q1 2015
    Published: 17-Dec-2014        Price: US $1295 Onwards        Pages: 130
    BMI View: The pharmaceutical and healthcare markets of the United Kingdom are driven by government spending in the form of the National Health System (NHS), which accounts for over 80% of total healthcare spending. With a higher prevalence of non-communicable diseases, coupled with an ageing population, the increased demand for healthcare may lead to the enforcement of cost-containment strategies and movement away from expensive treatment options. Headline Expenditure Projections Pharmaceuticals......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs